EGFR and neoplasm: Therefore, treatment with anti-EGFR mAbs previously only required confirmation of KRAS wild-type status; however, in 2013, the European Medicines Agency (EMA) revised the therapeutic indication, restricting it to patients with RAS wild-type mCRC tumours only.